Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

血管抑制剂 阿柏西普 医学 黄斑变性 自然科学 眼科 视力 加药 贝伐单抗 外科 内科学 化疗
作者
Faye Horner,Peck Lin Lip,Bashar Mohammed,William Fusi-Rubiano,Eesha Gokhale,Bushra Mushtaq,Randhir Chavan
出处
期刊:Clinical Ophthalmology [Dove Medical Press]
卷期号:Volume 15: 1703-1713 被引量:5
标识
DOI:10.2147/opth.s305141
摘要

To compare and report the 2-year treatment outcomes from 3 different anti-VEGF treatment regimens in treating neovascular aged-related macular degeneration (nAMD): Ranibizumab pro re nata (Ranibizumab-PRN); Ranibizumab treat and extend (Ranibizumab-T&E); Aflibercept fixed first year dosing (7 injections) with treat and extend in subsequent year (Aflibercept-Fixed).All treatment-naïve nAMD patients who completed 24 months of monitoring from a single treatment center were included. Patients received the initial loading dose of three injections (4-weekly interval), followed by one of the 3 treatment regimens. Primary outcomes were changes in visual acuity (VA) and central retinal thickness (CRT). Secondary outcome was number of injections required in each year. Data analysis included last observation carried forward (LOCF) for patients with incomplete year-2 follow-up.A total of 249 eyes (230 patients) were studied: 121 Ranibizumab-PRN; 65 Ranibizumab-T&E, and 63 Aflibercept-Fixed. Baseline median VA (ETDRS letters) for Ranibizumab-PRN, Ranibizumab-T&E, and Aflibercept-Fixed was 53.9, 61.1, and 54.9 letters, achieving final VA of 54.9, 65.1, and 65.1 letters, respectively. Hence, the number of letters increased at the end of 24 months for each group was +1.0 (Ranibizumab-PRN), +4.0 (Ranibizumab-T&E), highest +10.2 in Aflibercept-Fixed group. Median number of injections over 2 years (year-1/year-2) was 5/1 for Ranibizumab-PRN, 9/6 for Ranibizumab-T&E, and 7/5 for Aflibercept-Fixed. Both Ranibizumab-T&E and Aflibercept-Fixed also shared the same reduction of median CRT (115 µm), higher than Ranibizumab-PRN (83 µm).We report VA improvement from all three different treatment regimens with both Aflibercept-Fixed and Ranibizumab-T&E regimens achieving the same higher final VA. Aflibercept-Fixed dosing may have more favorable efficacy with the highest VA gain and comparatively lower dosing frequency whereas Ranibizumab-T&E may be more efficient than Ranibizumab-PRN regimen, according to our study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科目三应助阳光易真采纳,获得30
2秒前
yoyo发布了新的文献求助10
2秒前
思源应助Wl采纳,获得10
4秒前
共享精神应助橘笙采纳,获得10
5秒前
耍酷问兰发布了新的文献求助10
6秒前
科研通AI2S应助nczpf2010采纳,获得10
8秒前
搜集达人应助杜兰特工队采纳,获得10
13秒前
热心市民小红花应助牛马采纳,获得10
15秒前
热心市民小红花应助牛马采纳,获得10
15秒前
15秒前
Ava应助WJM采纳,获得10
19秒前
科研通AI2S应助nczpf2010采纳,获得10
20秒前
酷酷飞烟发布了新的文献求助10
20秒前
Bressanone发布了新的文献求助10
22秒前
李健的小迷弟应助老吴采纳,获得10
22秒前
大气的雅山完成签到,获得积分10
24秒前
shaoshao86完成签到,获得积分10
30秒前
30秒前
华仔应助科研通管家采纳,获得10
30秒前
逆时针应助科研通管家采纳,获得10
30秒前
MchemG应助科研通管家采纳,获得10
30秒前
研友_VZG7GZ应助科研通管家采纳,获得10
30秒前
wang应助科研通管家采纳,获得10
30秒前
wang应助科研通管家采纳,获得10
30秒前
ding应助科研通管家采纳,获得10
30秒前
上官若男应助科研通管家采纳,获得10
31秒前
思源应助科研通管家采纳,获得10
31秒前
田様应助科研通管家采纳,获得10
31秒前
小北发布了新的文献求助10
31秒前
NexusExplorer应助Quinna采纳,获得10
33秒前
34秒前
34秒前
量子星尘发布了新的文献求助10
36秒前
WJM发布了新的文献求助10
40秒前
老吴发布了新的文献求助10
41秒前
42秒前
佳语妍说完成签到,获得积分10
43秒前
44秒前
45秒前
酷波er应助平淡的凝竹采纳,获得10
46秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073